Prevention of murine implant-associated infection by SAAP-148-loaded bioactive glass S53P4 formulation

Introduction Orthopedic implant-associated infections are difficult to treat due to bacterial persistence in biofilms on implant surfaces and in surrounding tissues. Bioactive glass S53P4 (BAG) is a clinically used bone graft substitute with antibacterial properties resulting from surface reactivity and dissolution-mediated changes in the local microenvironment; however, its antibacterial efficacy against established infections with a high bacterial burden is limited. In this study we therefore developed BAG putty and cream formulations loaded with synthetic antimicrobial and antibiofilm peptide SAAP-148 to enhance local antibacterial activity. Methods Eluates from SAAP-148-loaded and unloaded BAG putty and cream formulations were tested in vitro against planktonic bacteria and biofilms of Staphylococcus aureus and Acinetobacter baumannii . Antibacterial efficacy was further assessed in cadaver mouse subcutaneous implant infection model as an intermediate validation step before evaluation in an in vivo mouse subcutaneous implant infection model using S. aureus . Results In vitro , SAAP-148-loaded BAG putty and BAG cream eluates eradicated planktonic bacteria as well as young and mature biofilms of S . aureus and A . baumannii . Eluates of BAG formulations without SAAP-148 had limited bactericidal activity, with BAG cream eluates slightly more bactericidal than BAG putty eluates. The enhanced antibacterial effects of SAAP-148-loaded BAG formulations were confirmed in a cadaver mouse subcutaneous implant infection model, where S. aureus was eradicated both on the implant surface and in the surrounding tissue, whereas BAG-only formulations showed limited antibacterial effect. In a subsequent in vivo mouse subcutaneous implant infection model, SAAP-148-loaded BAG putty eradicated S. aureus on the implant surface and markedly reduced bacterial burden in tissue, whereas BAG putty-only failed to reduce bacterial numbers. Conclusion Loading SAAP-148 into BAG putty and cream enhanced BAG antibacterial and antibiofilm activity, supporting its potential as a clinically relevant adjunct to the BAG’s antimicrobial activity for treating implant-associated infections.

Authors

Institutions

Publication Details

Journal
Frontiers in Bioengineering and Biotechnology
Published
2026-11-04
DOI
https://doi.org/10.3389/fbioe.2026.1959395
Primary Topic
Orthopedic Infections and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prevention of murine implant-associated infection by SAAP-148-loaded bioactive glass S53P4 formulation

Sebastian A. J. Zaat, Martijn Riool, Leonie de Boer, Deeksha Rajkumar et al.
Frontiers in Bioengineering and Biotechnology
Orthopedic Infections and Treatments
article

Prevention of murine implant-associated infection by SAAP-148-loaded bioactive glass S53P4 formulation

Sebastian A. J. Zaat, Martijn Riool, Leonie de Boer, Deeksha Rajkumar, Payal P. S. Balraadjsing
article en

Abstract

Introduction Orthopedic implant-associated infections are difficult to treat due to bacterial persistence in biofilms on implant surfaces and in surrounding tissues. Bioactive glass S53P4 (BAG) is a clinically used bone graft substitute with antibacterial properties resulting from surface reactivity and dissolution-mediated changes in the local microenvironment; however, its antibacterial efficacy against established infections with a high bacterial burden is limited. In this study we therefore developed BAG putty and cream formulations loaded with synthetic antimicrobial and antibiofilm peptide SAAP-148 to enhance local antibacterial activity. Methods Eluates from SAAP-148-loaded and unloaded BAG putty and cream formulations were tested in vitro against planktonic bacteria and biofilms of Staphylococcus aureus and Acinetobacter baumannii . Antibacterial efficacy was further assessed in cadaver mouse subcutaneous implant infection model as an intermediate validation step before evaluation in an in vivo mouse subcutaneous implant infection model using S. aureus . Results In vitro , SAAP-148-loaded BAG putty and BAG cream eluates eradicated planktonic bacteria as well as young and mature biofilms of S . aureus and A . baumannii . Eluates of BAG formulations without SAAP-148 had limited bactericidal activity, with BAG cream eluates slightly more bactericidal than BAG putty eluates. The enhanced antibacterial effects of SAAP-148-loaded BAG formulations were confirmed in a cadaver mouse subcutaneous implant infection model, where S. aureus was eradicated both on the implant surface and in the surrounding tissue, whereas BAG-only formulations showed limited antibacterial effect. In a subsequent in vivo mouse subcutaneous implant infection model, SAAP-148-loaded BAG putty eradicated S. aureus on the implant surface and markedly reduced bacterial burden in tissue, whereas BAG putty-only failed to reduce bacterial numbers. Conclusion Loading SAAP-148 into BAG putty and cream enhanced BAG antibacterial and antibiofilm activity, supporting its potential as a clinically relevant adjunct to the BAG’s antimicrobial activity for treating implant-associated infections.

Frontiers in Bioengineering and BiotechnologyVol. 14
University Hospital Regensburg (DE), Amsterdam University Medical Centers (NL), Amsterdam institute for Immunology and Infectious Diseases (NL), University of Amsterdam (NL)
Openalex Percentile: Top 11%
Orthopedic Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon